Pressure Ulcer Biologics: A Clinical Decision Framework

Clinical Context

Pressure ulcers remain a high-burden problem across acute, post-acute, and long-term care settings. National clinical guidelines recommend a broad range of preventative and curative interventions, yet the effectiveness of many dressings, support surfaces, and topical agents is still uncertain. For clinicians, the practical question is not whether to follow guidelines, but how to sequence risk assessment, prevention, and advanced biologics when a wound fails to progress.

Risk Assessment and Decision Pathways

Every pressure ulcer protocol starts with risk stratification. A decision-tree approach using the activity, mobility, and skin moisture subscales of the Braden Scale provides an objective foundation for rapid clinical judgment in immobilized patients.

Recent best-evidence work in orthopaedic patients reinforces the structure of an effective prevention program. A systematic review of 15 literature sources produced 34 evidence-based recommendations across six domains: risk assessment, position management, skin care, device-related pressure injury prevention, nutritional assessment and support, and health education and training.

Prevention: What the Evidence Shows

Prevention evidence is more nuanced than product marketing often suggests. The PRESSURE 2 randomized controlled trial compared alternating pressure mattresses (APMs) with high-specification foam mattresses (HSFMs) in 2,029 high-risk inpatients. Overall, 7.9% of participants developed a new category 2 or higher pressure ulcer within 30 days. The trial did not find a statistically significant difference between mattresses over the full follow-up period, though a treatment-phase sensitivity analysis favored APMs. The authors concluded that decisions should be individualized based on skin status, mobility, rehabilitation needs, and patient tolerance.

Dressings and topical agents for prevention have been evaluated in 51 randomized trials with over 13,000 participants. Some comparisons, such as silicone foam versus no dressing and hydrocolloid versus no dressing, showed relative risk reductions in incidence. However, the evidence was rated as low or very low certainty, and the Cochrane authors concluded that it is unclear whether any of the studied dressings or topical agents make a meaningful difference in pressure ulcer development.

When Standard Care Is Not Enough: Biologics in the Algorithm

Many pressure ulcers stall because of persistent inflammation, protease imbalance, or impaired angiogenesis despite adequate offloading and wound bed preparation. When a wound does not progress after two to four weeks of optimized standard care, advanced biologics become a rational next step.

Amniotic membrane allografts are advanced wound biologics intended for chronic, non-healing wounds. Products such as AmnioAMP and Rampart are used as adjuncts to standard of care, not replacements for offloading, nutrition, moisture management, or infection control. The decision to apply a biologic should be made after documented failure of foundational measures and should be paired with continued reassessment of healing trajectory.

A Practical Sequencing Protocol

• Admit/initial visit: Apply a validated risk scale and document Braden activity, mobility, and moisture status.
• Hours 0-24: Implement individualized offloading and support surface selection based on mobility, skin status, and patient tolerance.
• Days 1-7: Optimize skin care, manage moisture, audit medical devices, and initiate nutrition assessment.
• Week 2-4: Reassess wound healing. If there is no measurable improvement, review and correct modifiable barriers.
• After optimized standard care: Consider amniotic membrane biologics such as AmnioAMP or Rampart for refractory wounds.
• Ongoing: Continue reassessment, photograph, and adjust the plan based on response.

Key Takeaways

• Pressure ulcer prevention is multi-modal and should be individualized; no single dressing or mattress fits every patient.
• Decision support tools improve structure, but their impact on hard clinical outcomes remains limited in current evidence.
• Advanced biologics belong later in the algorithm, after documented failure of offloading, nutrition, and wound-bed optimization.
• Honest, evidence-based patient selection and documentation protect both the patient and the practice.